Navigation Links
Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Date:9/8/2010

n the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2009.
Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Forward Looking Statements: Regeneron Pharmaceuticals, Inc.This news release includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties. These include, among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Astellas, the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarter ended June 30, 2010. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise,
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Mike Rowe , spokesperson and reality television ... Pharmacy,s 2015 ThoughtSpot conference and tradeshow, which ... Las Vegas, Nev. Best known ... and Discovery Channel,s, "Dirty Jobs," Mr. Rowe spent a decade ... – people whose hard work, sacrifice and value aren,t always ...
(Date:7/28/2015)...  CryoLife, Inc. (NYSE: CRY ), a leading ... and vascular surgery, announced today its results for the ... Pat Mackin, Chairman, President and Chief Executive ... on our growth strategy with solid progress on several ... plans to transition to a direct sales model in ...
(Date:7/28/2015)... YORK , July 28, 2015 ... late-stage pharmaceutical company focused on the development and ... that new Locilex® microbiology data will be presented ... of Antimicrobial Agents and Chemotherapy and International Society ... (ICAAC/ICC 2015) scientific meeting in San ...
Breaking Medicine Technology:Mike Rowe to Address Community Pharmacists at ThoughtSpot 2015 2CryoLife Reports Second Quarter Financial Results 2CryoLife Reports Second Quarter Financial Results 3CryoLife Reports Second Quarter Financial Results 4CryoLife Reports Second Quarter Financial Results 5CryoLife Reports Second Quarter Financial Results 6CryoLife Reports Second Quarter Financial Results 7CryoLife Reports Second Quarter Financial Results 8CryoLife Reports Second Quarter Financial Results 9CryoLife Reports Second Quarter Financial Results 10CryoLife Reports Second Quarter Financial Results 11CryoLife Reports Second Quarter Financial Results 12CryoLife Reports Second Quarter Financial Results 13CryoLife Reports Second Quarter Financial Results 14Dipexium Pharmaceuticals' Pexiganan Demonstrates Microbiological Activity Against Pathogens Resistant to other Topical Antibiotics 2Dipexium Pharmaceuticals' Pexiganan Demonstrates Microbiological Activity Against Pathogens Resistant to other Topical Antibiotics 3
... A study comparing,the formulations of isosorbide dinitrate (ISDN) ... II, and BiDil, the proprietary,fixed dose combination, used ... no bioequivalence. Non-bioequivalence,in the formulations used may explain ... results in decreasing mortality. Using,identical amounts of active ...
... 26, 2007 /PRNewswire/ -- DiObex,Inc., a privately- ... therapeutics to treat metabolic diseases, today,announced positive ... novel Cortisol,Synthesis Inhibitor. , In a recently ... 2 diabetes were,treated for two weeks to ...
Cached Medicine Technology:Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 2Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 3Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 4Study: Identical Doses of BiDil Components Are Not Bioequivalent to,the Fixed Dose Combination-BiDil-Used in A-HeFT 5Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes 2Diobex Announces Successful Completion of Phase 2a Trial Of,DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes 3
(Date:7/28/2015)... Nashville, Tenn. (PRWEB) , ... July 28, 2015 ... ... has added the SmileCareClub Invisible Aligner System to its online product ... , By using a teledentistry model and cloud-based technology, SmileCareClub allows patients to ...
(Date:7/28/2015)... Wayne, PA (PRWEB) , ... July 28, 2015 ... ... that its Board of Directors has authorized the Company, from time to time ... with an aggregate value of up to $25 million. Repurchases will be made ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... services to include a proprietary, web based clinical knowledge system, called “Referral Guidance.” ... evidence based. It provides physicians who are anticipating making a subspecialty referral ...
(Date:7/28/2015)... ... 2015 , ... Fertility specialist Dr. Lisa Hasty of Atlanta Center ... Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has been recognized for ... in the metro area as one of the most respected doctors in Reproductive Endocrinology. ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new study published ... Fibromyalgia, Study Says " sheds light on a possible new treatment option for people ... months of regular HBOT sessions, at least five per week, patients experienced a significant ...
Breaking Medicine News(10 mins):Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 2Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 3Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3
... - Region,s Fastest Growing Private Company* Delivers Quality, ... in Patients, Needs -, GLENDALE, Calif., Nov. ... (2005 through 2007) earned it the status as ... the region,s top business media,Lakeside Systems, Inc. (Lakeside) ...
... Increases Fund Size for Venture Team by 30%, ... Ventures (, http://www.morgenthaler.com/ventures ), a leading venture ... today that it has exceeded its,fundraising goal and ... $400,million. This brings the firm,s total capital under ...
... PLC Systems Inc.,(Pink Sheets: PLCSF), a company ... today stated that, following the,delisting of its common ... Stock Exchange) on Monday, November 10, 2008, the ... its common stock listing to the,OTCBB. Until that ...
... articles that stress African-American health disparities, like higher ... black patients from being screened for cancer, according ... are more likely to be tested for cancer ... among African-American cancer patients. , While the medical ...
... International Conference on Wireless ... Identification in Milan, HATBORO, Pa., ... of enterprise mobility and advanced,wireless asset tracking solutions for the healthcare ... on the predictive value of identification technology at the ID,WORLD International ...
... Closed in 2008, According to New Report,from HealthLeaders-InterStudy, ... provider of managed care market intelligence, reports that ... better than health systems,in other parts of the ... to the new Southern New Jersey Market Overview, ...
Cached Medicine News:Health News:Lakeside Systems, Inc. Unifies Integrated Healthcare Delivery System under New Brand: Lakeside Community Healthcare 2Health News:Lakeside Systems, Inc. Unifies Integrated Healthcare Delivery System under New Brand: Lakeside Community Healthcare 3Health News:Lakeside Systems, Inc. Unifies Integrated Healthcare Delivery System under New Brand: Lakeside Community Healthcare 4Health News:Morgenthaler Closes Ninth Fund at $400 Million 2Health News:Morgenthaler Closes Ninth Fund at $400 Million 3Health News:Morgenthaler Closes Ninth Fund at $400 Million 4Health News:PLC Systems Updates Common Stock Listing Status 2Health News:Messages of hope work better in motivating black patients to seek early screening for cancer 2Health News:InfoLogix CEO to Address Hidden Value of ID Technology at International Conference 2Health News:InfoLogix CEO to Address Hidden Value of ID Technology at International Conference 3Health News:Southern New Jersey Hospitals Thriving, but Cautious in Light of Market Conditions 2Health News:Southern New Jersey Hospitals Thriving, but Cautious in Light of Market Conditions 3
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... solution tricompartmental total knee prosthesis stems from ... State-of-the-art design and manufacturing technologies have been ... function as well as a favorable pressure ... to keep wear to a minimum. The ...
... system continues the "Consensus Concept" approach to ... diversified experience of a Scientific Advisory Board. ... that incorporates state-of-the-art features. Consensus Knee implants ... implant stability and allow near normal kinematics. ...
Medicine Products: